Stability of mono- and trivalent meningococcal outer membrane vesicle vaccines

被引:56
作者
Arigita, C
Jiskoot, W
Westdijk, J
van Ingen, C
Hennink, WE
Crommelin, DJA
Kersten, GFA
机构
[1] Netherlands Vaccine Inst, Res & Dev Unit, NL-3720 BA Bilthoven, Netherlands
[2] Univ Utrecht, Dept Pharmaceut, UIPS, NL-3508 TB Utrecht, Netherlands
关键词
Neisseria meningitidis; PorA; vesicle; vaccine; stability; freeze-drying;
D O I
10.1016/j.vaccine.2003.08.027
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The stability during storage of outer membrane vesicles (OMVs) of Neisseria meningitidis group B was studied. Three types of OMVs were compared for their stability, containing either one (monovalent) or three different PorA subtypes (trivalent), the latter with and without class 4 outer membrane protein (OMO, RmpM). Aqueous formulations were stored freeze-dried (4 degreesC), frozen (-70 degreesC) and in liquid form at 4, 37 and 56 degreesC. Physico-chemical properties and immunogenicity of the OMVs as well as PorA conformation and antigenicity (P1.7-2,4, the subtype present in all formulations) were monitored during 1 year. At -70 or 4 degreesC, the structure and immunogenicity of OMVs was preserved. Storage of OMVs at high temperatures (37 or 56degreesC) induced destruction of the OMV structure and denaturation of PorA, followed by chemical degradation. Immunogenicity decreased or was lost completely. Changes observed in the fluorescence spectra of degraded OMVs were also seen in tryptophan (Trp) and tyrosine (Tyr) derivatives incubated at 56 degreesC, indicating the occurrence of chemical degradation of tryptophan and tyrosine residues in PorA. Trivalent OMVs were slightly more stable at 37 degreesC than monovalent OMVs as assessed by in vitro methods, but these differences did not result in differences in the immunogenicity. The stability of trivalent OMVs was not affected by the presence of RmpM. Both trivalent and monovalent OMVs could be freeze-dried with preservation of their immunogenicity. In conclusion, OMVs are sensitive to elevated temperatures, but are stable in the frozen or freeze-dried state or when stored at 4 degreesC in the liquid state. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:629 / 642
页数:14
相关论文
共 29 条
[1]   WHOLE-CELL ELISA FOR TYPING NEISSERIA-MENINGITIDIS WITH MONOCLONAL-ANTIBODIES [J].
ABDILLAHI, H ;
POOLMAN, JT .
FEMS MICROBIOLOGY LETTERS, 1987, 48 (03) :367-371
[2]   OUTER-MEMBRANE PHOE PROTEIN OF ESCHERICHIA-COLI AS A CARRIER FOR FOREIGN ANTIGENIC DETERMINANTS - IMMUNOGENICITY OF EPITOPES OF FOOT-AND-MOUTH-DISEASE VIRUS [J].
AGTERBERG, M ;
ADRIAANSE, H ;
LANKHOF, H ;
MELOEN, R ;
TOMMASSEN, J .
VACCINE, 1990, 8 (01) :85-91
[3]   Restored functional immunogenicity of purified meningococcal PorA by incorporation into liposomes [J].
Arigita, C ;
Kersten, GFA ;
Hazendonk, T ;
Hennink, WE ;
Crommelin, DJA ;
Jiskoot, W .
VACCINE, 2003, 21 (9-10) :950-960
[4]   EFFECT OF OUTER-MEMBRANE VESICLE VACCINE AGAINST GROUP-B MENINGOCOCCAL DISEASE IN NORWAY [J].
BJUNE, G ;
HOIBY, EA ;
GRONNESBY, JK ;
ARNESEN, O ;
HOLSTFREDRIKSEN, J ;
HALSTENSEN, A ;
HOLTEN, E ;
LINDBAK, AK ;
NOKLEBY, H ;
ROSENQVIST, E ;
SOLBERG, LK ;
CLOSS, O ;
ENG, J ;
FROHOLM, LO ;
LYSTAD, A ;
BAKKETEIG, LS ;
HAREIDE, B .
LANCET, 1991, 338 (8775) :1093-1096
[5]   Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine [J].
Claassen, I ;
Meylis, J ;
vanderLey, P ;
Peeters, C ;
Brons, H ;
Robert, J ;
Borsboom, D ;
vanderArk, A ;
vanStraaten, I ;
Roholl, P ;
Kuipers, B ;
Poolman, J .
VACCINE, 1996, 14 (10) :1001-1008
[6]   Serum bactericidal activity and isotype distribution of antibodies in toddlers and schoolchildren after vaccination with RIVM hexavalent PorA vesicle vaccine [J].
de Kleijn, E ;
van Eijndhoven, L ;
Vermont, C ;
Kuipers, B ;
van Dijken, H ;
Rümke, H ;
de Groot, R ;
van Alphen, L ;
van den Dobbelsteen, G .
VACCINE, 2001, 20 (3-4) :352-358
[7]   Immunogenicity and safety of monovalent P1.7h,4 meningococcal outer membrane vesicle vaccine in toddlers:: comparison of two vaccination schedules and two vaccine formulations [J].
de Kleijn, ED ;
de Groot, R ;
Lafeber, AB ;
Labadie, J ;
van Limpt, KCJP ;
Visser, J ;
Berbers, GAM ;
van Alphen, L ;
Rümke, HC .
VACCINE, 2000, 19 (9-10) :1141-1148
[8]   Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age [J].
de Kleijn, ED ;
de Groot, R ;
Labadie, J ;
Lafeber, AB ;
van den Dobbelsteen, G ;
van Alphen, L ;
van Dijken, H ;
Kuipers, B ;
van Omme, GW ;
Wala, M ;
Juttmann, R ;
Rümke, HC .
VACCINE, 2000, 18 (15) :1456-1466
[9]  
DEMORAES JC, 1992, LANCET, V340, P1074
[10]  
FINNE J, 1987, J IMMUNOL, V138, P4402